GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Johnson & Johnson

Thermo Fisher Scientific

It looks like 2019's going to be much better than expected for these giants operating in different corners of the healthcare sector.

Three Healthcare Stocks With Rising Expectations.

Glaxo (GSK) beats on earnings and sales in the second quarter. Strong growth of vaccine and respiratory portfolio boosts sales.

Glaxo (GSK) Beats on Q2 Earnings, Shingrix Sales Strong

GlaxoSmithKline PLC (GSK) CEO Emma Walmsley on Q2 2019 Results - Earnings Call Transcript

GlaxoSmithKline  beat second quarter profit expectations with the help of strong demand for its shingles vaccine, prompting the British drugmaker to forecast a smaller fall in profit this year than originally anticipated.

GSK raises 2019 earnings expectations after standout quarter for Shingrix

Alexion Pharma

Drugmakers GlaxoSmithKline and Alexion Pharmaceuticals topped second-quarter earnings forecasts on Wednesday. In premarket trading, GSK stock rose 1%, and Alexion stock jumped 2.9%.

Pharma Giant Tops Estimates And Predicts Smaller Dip In 2019 Profit

Glaxo beats both earnings and sales estimates in the second quarter of 2019.

Glaxo (GSK) Beats Earnings & Revenue Estimates in Q2

Pharmaceutical giant GlaxoSmithKline GSK, +0.46% GSK, -0.82% said Wednesday that Jonathan Symonds will succeed Phillip Hampton as non-executive chairman.

GlaxoSmithKline says Symonds will become chairman

Glaxo (GSK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Glaxo (GSK) Ahead of Earnings?

Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer meets the primary endpoint.

Glaxo's Zejula Meets Goal in First-Line Ovarian Cancer Study

GlaxoSmithKline Plc  is in talks to name HSBC's deputy chairman Jonathan Symonds as the next chairman of the British drugmaker, Bloomberg reported on Sunday, citing a person familiar with the matter.

GSK in talks to name HSBC's Symonds as its next chairman: Bloomberg

Glaxo's (GSK) phase III study, evaluating the efficacy of switching to Dovato from a three-drug TAF based regimen, meets the primary endpoint.

Glaxo's Two-Drug HIV Pill Dovato on Par with Three-Drug Pill

HIV patients may soon be eligible for a less burdensome dosing regimen based on the positive results announced Wednesday by GlaxoSmithKline plc (NYSE: GSK)-owned ViiV Healthcare for a late-stage study of its two-drug regimen for the disease.

Study: ViiV Healthcare's 2-Drug HIV Regimen As Effective As 3

Glaxo's (GSK) long-acting, injectable two-drug regimen gets FDA's priority review designation. The company begins study to identify approaches to implementing once-monthly injectable HIV treatment in the real world.

Glaxo's Long-Acting HIV Regimen Gets FDA's Priority Status

AbbVie

Bayer AG

Eli Lilly

Merck

Novartis

Pfizer

Roche Holding AG

Sanofi

SPDR S&P Pharmaceuticals ETF

"We're working on it right now a favored nations clause where we pay the lower nation's price is, like Canada," President Donald Trump tells reporters.

Trump says administration preparing an executive order on drug prices

Glaxo (GSK) gets an EU approval for Dovato, its single-tablet two-drug HIV regimen. It commences phase III studies on its anti GM-CSF antibody, otilimab, for patients with rheumatoid arthritis.

Glaxo's Dovato Wins EU Nod, RA Candidate Enters Phase III

Liver Therapy Forum weekly digest provides an overview on what’s happening in liver diseases in 2019. This week focuses on GlaxoSmithKline plc.

GlaxoSmithKline And Linerixibat In Cholestasis Pruritus: It Is Worth A Look

iShares International Dividend Growth ETF

Royal Bank of Canada

Unilever

With international dividend stocks, valuations are generally better and yields are bigger. Here are five stocks that stand out.

5 Dividend Stocks to Buy From Across the Globe

These biopharma stocks to buy could also be a retiree's dream stocks.

3 Biopharma Stocks to Buy for Income

GlaxoSmithKline has offered concessions to address EU antitrust concerns over its planned joint venture with Pfizer's consumer health business, the European Commission said on Thursday.

GSK offers concessions to address EU concerns over Pfizer deal

Glaxo (GSK) signs a five-year collaboration contract with the University of California to build a new laboratory for developing new medicines with the aid of CRISPR technologies.

Glaxo Inks Genome Research Deal With University of California

American Express

Danaher

Lockheed Martin

Rio Tinto plc Sponsored

Starbucks

According to the GuruFocus All-in-One Screener, the following companies look cheap since they are trading with low price-sales ratios.

6 Guru Stocks With Low Price-Sales Ratios

We May Pick Up GlaxoSmithKline At Cheaper Prices

Private equity-backed generic drugmaker Stada said on Friday it would buy six consumer healthcare products from British drugmaker GlaxoSmithKline to bolster its presence in Europe.

Germany's Stada buys six of GSK's consumer brands, eyes further deals

GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.

Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options

GlaxoSmithKline plans to launch Shingrix in China in several phases starting 2020.

Glaxo's Shingles Vaccine Shingrix Gets Approval in China

News for GlaxoSmithKline Stock (GSK)